The forecast for Nervous System Medicine sales in Switzerland from 2024 to 2028 shows a steady increase in value, with figures projected to rise from 139.5 USD PPP per capita in 2024 to 150.5 USD PPP per capita by 2028. The actual sales value in 2023 stood at 137 USD PPP per capita.
The year-on-year percentage variations for the forecasted period are as follows:
- 2024: +1.8%
- 2025: +2%
- 2026: +1.9%
- 2027: +1.9%
- 2028: +1.8%
The compound annual growth rate (CAGR) over the five-year forecast period is approximately 1.9% per annum.
Looking ahead, future trends to watch for include advancements in neurological research, the introduction of new medications, and policy changes in healthcare that may impact the availability and pricing of nervous system medicines. Additionally, demographic shifts, particularly an aging population, could drive demand and influence market dynamics.
